The PE Ratio as of September 2024 (TTM) for Genfit S.A. (GNFT) is -6.46

According to Genfit S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -6.46. This represents a change of 19.05% compared to the average of -5.43 of the last 4 quarters.

Genfit S.A. (GNFT) Historical PE Ratio (quarterly & annually)

How has GNFT PE Ratio performed in the past?

The mean historical PE Ratio of Genfit S.A. over the last ten years is -11.05. The current -6.46 PE Ratio has changed 5.75% with respect to the historical average. Over the past ten years (40 quarters), GNFT's PE Ratio was at its highest in in the March 2021 quarter at 10.36. The PE Ratio was at its lowest in in the December 2015 quarter at -29.57.

Genfit S.A. (GNFT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Genfit S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genfit S.A. (GNFT) Average PE Ratio

How has GNFT PE Ratio performed in the past?

The current PE Ratio of Genfit S.A. (GNFT) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Genfit S.A. (GNFT) PE Ratio vs. Peers

How is GNFT’s PE Ratio compared to its peers?

Genfit S.A.’s PE Ratio is less than Cyteir Therapeutics, Inc. (-3.52), less than ERYTECH Pharma S.A. (27.26), less than Eliem Therapeutics, Inc. (-3.90), less than HCW Biologics Inc. (-0.59), less than Molecular Partners AG (-2.54), greater than MediciNova, Inc. (-10.99), less than Anebulo Pharmaceuticals, Inc. (-5.80), greater than Champions Oncology, Inc. (-20.54), greater than Keros Therapeutics, Inc. (-12.00), greater than Janux Therapeutics, Inc. (-61.03), less than Fennec Pharmaceuticals Inc. (53.32), greater than Edgewise Therapeutics, Inc. (-13.72), less than Harmony Biosciences Holdings, Inc. (19.22), less than Aerovate Therapeutics, Inc. (-0.63), less than Adagene Inc. (-3.10), less than Acrivon Therapeutics, Inc. Common Stock (-4.45), less than Rezolute, Inc. (-4.50), less than AN2 Therapeutics, Inc. (-0.48),

Build a custom stock screener for Genfit S.A. (GNFT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genfit S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genfit S.A. (GNFT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genfit S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.